SLC6A3 and Parkinson disease: Jeong et al. observed a beneficial effect of DPP4-i in a small group of diabetic patients with Parkinson’s disease: they found a higher baseline dopamine transporter availability and better motor performance compared to non-diabetic patients (Jeong et al., 2021).